SUPNHealthcare · Drug Manufacturers - Specialty & GenericThe 4 Wall Street analysts covering Supernus Pharmaceuticals, Inc. hold a median 12-month price target of $63 — +50.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 79 of 100 as at 12 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Supernus Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (96): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (38): The company has been issuing shares or taking on financing, diluting existing holders.
Size (33): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on SUPN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +50.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 July 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 9 July 2026 | Cantor Fitzgerald | Maintains | Overweight | $63 → $67 |
| 19 Dec 2025 | Stifel | Maintains | Hold | — |
| 29 Oct 2025 | B of A Securities | Initiates | Buy | — |
| 23 Oct 2025 | TD Cowen | Maintains | Buy | — |
| 9 Oct 2025 | Piper Sandler | Upgrade | Overweight | — |
| 30 Sept 2025 | Cantor Fitzgerald | Maintains | Overweight | — |
| 29 Aug 2025 | Piper Sandler | Maintains | Neutral | — |
| 6 Aug 2025 | Cantor Fitzgerald | Maintains | Overweight | — |
| 26 Feb 2025 | Cantor Fitzgerald | Reiterates | Neutral | — |
| 19 Feb 2025 | Cantor Fitzgerald | Downgrade | Neutral | — |
| 11 Sept 2024 | Piper Sandler | Downgrade | Neutral | — |
| 28 Feb 2024 | Piper Sandler | Maintains | Overweight | — |
| 9 Nov 2023 | Piper Sandler | Maintains | Overweight | — |
| 25 Oct 2023 | Piper Sandler | Maintains | Overweight | — |
| 10 May 2023 | Piper Sandler | Maintains | Overweight | — |
| 23 Jan 2023 | Piper Sandler | Maintains | Overweight | — |
| 31 Aug 2022 | Piper Sandler | Maintains | Overweight | — |
| 13 Apr 2021 | Jefferies | Upgrade | Buy | — |
| 16 June 2020 | Piper Sandler | Upgrade | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SUPN appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, Supernus Pharmaceuticals, Inc. returned −10.8% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 18% of US stocks
Cheaper than 42% of US stocks
Cheaper than 40% of US stocks
Cheaper than 16% of US stocks
Higher than 79% of US stocks
Higher than 67% of US stocks
Higher than 94% of US stocks
Higher than 30% of US stocks
Higher than 18% of US stocks
Higher than 35% of US stocks
Higher than 45% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Supernus Pharmaceuticals, Inc. has a market value of $2.4B and an enterprise value of $2.1B.
Revenue in the twelve months to 30 June 2026: $830.4M. The latest quarter grew 32.4% year on year.
Net income over the same four quarters: −$109.9M, a −13.2% net margin.
Diluted earnings per share, trailing twelve months: $−1.92.
Free cash flow in the twelve months to 30 June 2026: $18.8M.
Trailing P/E: 40.7×; forward P/E: 9.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Supernus Pharmaceuticals, Inc. employs 778 people — $1.1M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Supernus Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Supernus Pharmaceuticals announced that its management will participate in several investor conferences scheduled for September. The biopharmaceutical company, which develops CNS treatments, will be represented at these events.
Why it matters — Investor conferences give management a platform to present the company's progress and strategy to the investment community.
Supernus Pharmaceuticals announced that professional snowboarder Chloe Kim is partnering with the company as a compensated ambassador to discuss her ADHD diagnosis and treatment with Qelbree, a once-daily non-stimulant medication for patients aged 6 and older. Kim will share her lived experience to challenge misconceptions about ADHD and encourage others to advocate for their health and consult their doctors about potential treatment plans.
Why it matters — The high-profile ambassador partnership could raise awareness and visibility for Qelbree, Supernus' #1 prescribed branded non-stimulant ADHD treatment, potentially supporting brand awareness and patient engagement.
Halper Sadeh LLC, an investor rights law firm, announced it is investigating the proposed sale of Supernus Pharmaceuticals, Inc. to Indivior Pharmaceuticals, Inc., under which Supernus shareholders would receive 1.5401 common shares of Indivior for each Supernus share. The firm is examining whether the transaction provides a fair price to Supernus shareholders and is inviting them to learn about their rights.
Why it matters — The investigation raises questions about whether the proposed acquisition price is fair, which could affect the outcome of the deal and the value Supernus shareholders ultimately receive.
The news item reports that recent movements in the options market for Supernus Pharmaceuticals (SUPN) have drawn attention, raising the question of whether the options market is predicting a spike in the stock. It suggests investors need to pay close attention to SUPN based on this options activity.
Why it matters — A SUPN watcher would care because unusual options-market movements can signal shifting investor expectations about the stock's near-term price direction.
Indivior has proposed a merger with Supernus that could broaden its central nervous system portfolio, cut costs, and reduce its reliance on Sublocade, though the deal's closing remains uncertain.
Why it matters — For Supernus watchers, the proposed merger signals a potential expansion of its CNS portfolio and cost synergies, though completion is not yet assured.
The 4 Wall Street analysts covering Supernus Pharmaceuticals, Inc. have a median 12-month price target of $63, with estimates ranging from $55 to $67. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Supernus Pharmaceuticals, Inc., 3 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Supernus Pharmaceuticals, Inc. 79 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, Supernus Pharmaceuticals, Inc. ranks 79 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (96 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +50.1% from the last close, and Ticker Nerd's factor model ranks Supernus Pharmaceuticals, Inc. 79 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Supernus Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SUPN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $55 to $67 over the next 12 months.
Supernus Pharmaceuticals, Inc. returned -10.8% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for central nervous system diseases.
The most recent item we track (GlobeNewsWire, 2 Sept 2026): "Supernus Pharmaceuticals to Participate in September Investor Conferences". Supernus Pharmaceuticals announced that its management will participate in several investor conferences scheduled for September. The biopharmaceutical company, which develops CNS treatments, will be represented at these events.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for central nervous system diseases. Supernus Pharmaceuticals, Inc. markets therapies for neurological and psychiatric conditions such as attention-deficit hyperactivity disorder, epilepsy, migraine, Parkinson’s disease-related symptoms, cervical dystonia, chronic sialorrhea, and postpartum depression. Its current portfolio includes branded medicines used in neurology and psychiatry, with products sold primarily in the United States through specialty commercial channels. The company also maintains research and development programs aimed at advancing new CNS treatments and strengthening its neuroscience portfolio. Headquartered in Rockville, Maryland, Supernus Pharmaceuticals, Inc. plays a notable role in the specialty pharmaceutical market by addressing a broad range of chronic and complex disorders affecting the central nervous system.
CEO Mr. Jack A. Khattar M.B.A. · 778 employees · United States · https://www.supernus.com
